Pages that link to "Q74608094"

The following pages link to Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone (Q74608094):

Displaying 25 items.

• Parkinson’s disease psychosis 2010: A review article (Q22251238) (← links)
• Atypicality of atypical antipsychotics (Q24535908) (← links)
• Agitation in the ICU: part one Anatomical and physiologic basis for the agitated state (Q24795177) (← links)
• Role of the dopamine transporter in mediating the neuroleptic-induced reduction of tyrosine hydroxylase-immunoreactive midbrain neurons (Q28573996) (← links)
• Atypical presentations of atypical antipsychotics (Q34396636) (← links)
• Effects of newer antipsychotics on extrapyramidal function (Q34481227) (← links)
• Pathophysiology and treatment of psychosis in Parkinson's disease: a review (Q34610608) (← links)
• The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? (Q34659357) (← links)
• Atypical antipsychotics in the EPS-vulnerable patient (Q35035142) (← links)
• Treatment of psychosis in Parkinson's disease: safety considerations (Q35157477) (← links)
• Rationale for current therapies in Parkinson’s disease (Q35548168) (← links)
• Neurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol Administration (Q35987580) (← links)
• Drug-induced parkinsonism in the elderly: incidence, management and prevention (Q37976411) (← links)
• Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology (Q39080693) (← links)
• The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview (Q42664853) (← links)
• The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone, or olanzapine (Q42686193) (← links)
• Prosthetic systems for therapeutic optical activation and silencing of genetically-targeted neurons (Q42912175) (← links)
• Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice (Q44426248) (← links)
• Does early antipsychotic response predict long-term treatment outcome? (Q48283069) (← links)
• Management of behavioral and psychiatric problems in Parkinson's disease (Q48712930) (← links)
• Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra (Q48869870) (← links)
• Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies (Q73101582) (← links)
• Dementia with Lewy bodies (Q80690619) (← links)
• Antipsychotic-induced extrapyramidal syndromes in psychiatric practice: a case-control study (Q81358733) (← links)
• The development of antipsychotic drugs (Q90285776) (← links)